ArticleJournal of endocrinological investigation2026
Effects of vitamin D status and supplementation on MASLD severity in individuals with overweight or obesity: a cross-sectional study and randomized controlled trial.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeLifestyle modification is the cornerstone of metabolic dysfunction-associated steatotic liver disease (MASLD) management, but effective adjunctive therapies are lacking. We examined the association between serum 25-hydroxyvitamin D [25(OH)D] and non-invasive parameters of MASLD severity and evaluated whether vitamin D3 supplementation, as an adjunct to lifestyle modification, influenced these parameters in adults with overweight or obesity and MASLD.
methodsA cross-sectional analysis of 505 adults with overweight or obesity and MASLD assessed associations between serum 25(OH)D and non-invasive liver parameters. In a subsequent 24-week randomized controlled trial (RCT), 132 participants were randomly assigned 1:1 to the vitamin D3 group (14,000 IU/week plus lifestyle modification) or the control group (lifestyle modification alone).
resultsIn the cross-sectional analysis, serum 25(OH)D levels were independently and inversely associated with controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) (both P < 0.001). In the RCT, the vitamin D3 group showed a greater reduction in CAP than the control group [adjusted difference = -41.2 dB/m; 95% confidence interval (CI), -56.8 to -25.6; P < 0.01]. No significant difference was observed in LSM change between the two groups (adjusted difference = -0.9 kPa; 95% CI, -2.3 to 0.4; P = 0.17).
conclusionSerum 25(OH)D levels were inversely associated with non-invasive parameters of MASLD severity in adults with overweight or obesity. Adjunctive vitamin D3 supplementation may provide an additional benefit for CAP reduction alongside lifestyle modification, whereas its effects on LSM require further investigation.
trial registrationThe study was registered with the Chinese Clinical Trial Registry (ChiCTR2100044305) on 16 March 2021. https://www.chictr.org.cn/showproj.html?proj=123441 .
Indexed as
Identifiers
42474689What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.